Independent committee says Praxis' tremor drug trial unlikely to meet main goal
Feb 28 (Reuters) - Praxis Precision Medicines PRAX.O said on Friday an independent committee had recommended its tremor drug trial be stopped for futility, as it was unlikely to meet its main goal. (Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Praxis Precision Medicines
See all newsUS RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Praxis Precision Q2 net loss widens on higher expenses
Brief: Praxis Precision Q2 EPS USD -2.87